Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel

Br J Cancer. 2019 Sep;121(6):483-489. doi: 10.1038/s41416-019-0544-0. Epub 2019 Aug 7.

Abstract

Background: An early detection tool for EOC was constructed from analysis of biomarker expression data from serum collected during the UKCTOCS.

Methods: This study included 49 EOC cases (19 Type I and 30 Type II) and 31 controls, representing 482 serial samples spanning seven years pre-diagnosis. A logit model was trained by analysis of dysregulation of expression data of four putative biomarkers, (CA125, phosphatidylcholine-sterol acyltransferase, vitamin K-dependent protein Z and C-reactive protein); by scoring the specificity associated with dysregulation from the baseline expression for each individual.

Results: The model is discriminatory, passes k-fold and leave-one-out cross-validations and was further validated in a Type I EOC set. Samples were analysed as a simulated annual screening programme, the algorithm diagnosed cases with >30% PPV 1-2 years pre-diagnosis. For Type II cases (~80% were HGS) the algorithm classified 64% at 1 year and 28% at 2 years tDx as severe.

Conclusions: The panel has the potential to diagnose EOC one-two years earlier than current diagnosis. This analysis provides a tangible worked example demonstrating the potential for development as a screening tool and scrutiny of its properties. Limits on interpretation imposed by the number of samples available are discussed.

Trial registration: ClinicalTrials.gov NCT00058032.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Biomarkers, Tumor / blood*
  • Blood Proteins / analysis*
  • C-Reactive Protein / analysis*
  • CA-125 Antigen / blood*
  • Carcinoma, Ovarian Epithelial / blood
  • Carcinoma, Ovarian Epithelial / diagnosis*
  • Early Detection of Cancer / methods*
  • Female
  • Follow-Up Studies
  • Humans
  • Phosphatidylcholine-Sterol O-Acyltransferase / blood*
  • Prognosis
  • Prospective Studies
  • Retrospective Studies

Substances

  • Biomarkers, Tumor
  • Blood Proteins
  • CA-125 Antigen
  • plasma protein Z
  • C-Reactive Protein
  • LCAT protein, human
  • Phosphatidylcholine-Sterol O-Acyltransferase

Associated data

  • ISRCTN/ISRCTN22488978
  • ClinicalTrials.gov/NCT00058032